Table 1.
Incorporation of α4β7 and ICAM-1 in a panel of clinical and laboratory HIV-1 and SIV isolates of different clade and coreceptor usage phenotypes grown in activated primary human PBMC. All the clinical isolates were minimally passaged in vitro. The level of virion incorporation was evaluated by measuring the amount of captured p24Gag (or p27Gag for SIV) antigen by immunomagnetic beads armed with anti-ICAM-1/CD54 or anti-α4β7 monoclonal antibodies, and was color-coded in different shades of red (darker to lighter: >1000; 400–1000; 100–400; 0–100 pg/mL).
| Virus | Strain | Clade | Coreceptor usage |
Virion incorporation* |
|
|---|---|---|---|---|---|
| ICAM-1 | α4β7 | ||||
|
| |||||
| HIV-1 | 92UG037 | A | R5 | 9 | 406 |
| HIV-1 | BaL | B | R5 | 275 | 768 |
| HIV-1 | ADA | B | R5 | 305 | 451 |
| HIV-1 | JRFL | B | R5 | 11 | 1379 |
| HIV-1 | IIIB | B | X4 | 64 | 1385 |
| HIV-1 | 07USLD | B | X4 | 83 | 658 |
| HIV-1 | 07USLR | B | X4 | 50 | 1373 |
| HIV-1 | 92HT599 | B | R5×4 | 42 | 830 |
| HIV-1 | 93UG065 | D | X4 | 414 | 719 |
| HIV-1 | 93TH057 | E | R5 | 0 | 457 |
| HIV-1 | CMU06 | E | X4 | 0 | 233 |
| HIV-1 | 97BR019 | F | R5×4 | 0 | 733 |
| SIV | smE660.307 | n.a. | R5 | 200 | 508 |
| SIV | mac251.745 | n.a. | R5 | 235 | 1499 |
*
Amount of p24Gag (or p27Gag) antigen (in pg/mL) captured from normalized input virus.